Post-approval studies (Phase 4)Study completedNCT02637973
What this trial is testing
Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes
Who this might be right for
Type 2 DiabetesNon-alcoholic Fatty Liver Disease
The Deutsche Diabetes Forschungsgesellschaft e.V. 84